The partnership addresses growing demand for self-administered therapies with a scalable, ready-to-use injector platform.

The Swiss healthtech startup’s patented multi-tissue platform aims to make drug discovery faster, safer, and more human-relevant

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple cancers NOUS-209 is an off-the-shelf cancer immunotherapy designed to induce T cells against neoantigens present in tumors and precancer lesions in LS carriers Publication in Nature Medicine underscores significance of NOUS-209 clinical data and its innovative approach to inte

InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability.

Xenometrix has launched the Rapid Micronucleus MoA (Mode of Action) Telomere Centromere Kit, a next-generation assay that accelerates and improves mechanistic genotoxicity analysis.